{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T04:54:21Z","timestamp":1777524861949,"version":"3.51.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A definitive diagnosis of Alzheimer\u2019s disease (AD), even in the presence of co-morbid neuropathology (occurring in\u2009&gt;\u200950% of AD cases), is a significant unmet medical need that has obstructed the discovery of effective AD therapeutics. An AD-biomarker, the Morphometric Imaging (MI) assay on cultured skin fibroblasts, was used in a double-blind, allcomers (ages 55\u201390) trial of 3 patient cohorts: AD dementia patients, N\u2009=\u200925, all autopsy confirmed, non-AD dementia patients, N\u2009=\u200921\u2014all autopsy or genetically confirmed; and non-demented control (AHC) patients N\u2009=\u200927. Fibroblasts cells isolated from 3-mm skin punch biopsies were cultured on a 3-D Matrigel matrix with movement dynamics quantified by image analysis<jats:bold>.<\/jats:bold> From counts of all aggregates (N) in a pre-defined field image and measures of the average area (A) of aggregates per image, the number-to-area ratios in a natural logarithmic form Ln(A\/N) were determined for all patient samples. AD cell lines formed fewer large aggregates (cells clustered together) than non-AD or AHC cell lines<jats:bold>.<\/jats:bold> The cut-off value of Ln(A\/N)\u2009=\u20096.98 was determined from the biomarker values of non-demented apparently healthy control (AHC) cases. Unequivocal validation by autopsy, genetics, and\/or dementia criteria was possible for all 73 patient samples. The samples were collected from multiple centers\u2014four US centers and one center in Japan. The study found no effect of center-to-center variation in fibroblast isolation, cell growth, or cell aggregation values (Ln(A\/N)). The autopsy-confirmed MI Biomarker distinguished AD from non-AD\u00a0dementia (non-ADD)\u00a0patients and correctly diagnosed AD even in the presence of other co-morbid pathologies at autopsy (True Positive\u2009=\u200925, False Negative\u2009=\u20090, False Positive\u2009=\u20090, True Negative\u2009=\u200921, and Accuracy\u2009=\u2009100%. Sensitivity and specificity were calculated as 100% (95% CI\u2009=\u200984 to 100.00%). From these findings, the MI assay appears to detect AD with great accuracy\u2014even with abundant co-morbidity.\n<\/jats:p>","DOI":"10.1038\/s41598-022-21796-y","type":"journal-article","created":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T11:03:06Z","timestamp":1667300586000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Morphometric imaging biomarker identifies Alzheimer\u2019s disease even among mixed dementia patients"],"prefix":"10.1038","volume":"12","author":[{"given":"Florin V.","family":"Chirila","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Fontaine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grant","family":"Kern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tapan K.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Brandt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerhard","family":"Nebe-von-Caron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"Charles L.","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel L.","family":"Alkon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,1]]},"reference":[{"key":"21796_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3684","volume":"371","author":"J Shi","year":"2020","unstructured":"Shi, J., Sabbagh, M. N. & Villas, B. Alzheimer's disease beyond amyloid: strategies for future therapeutic inventions.\u00a0BNJ 371, m3684 (2020).","journal-title":"BMJ"},{"key":"21796_CR2","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.neurobiolaging.2008.07.010","volume":"31","author":"TK Khan","year":"2010","unstructured":"Khan, T. K. & Alkon, D. L. Early diagnostic accuracy and pathophysiologic relevance of an Autopsy-confirmed Alzheimer\u2019s disease peripheral biomarker. Neurobiol. Aging 31, 889\u2013900 (2010).","journal-title":"Neurobiol. Aging"},{"key":"21796_CR3","doi-asserted-by":"publisher","first-page":"a006213","DOI":"10.1101\/cshperspect.a006213","volume":"2","author":"KA Johnson","year":"2012","unstructured":"Johnson, K. A., Fox, N. C., Sperling, R. A. & Klunk, W. E. Brain imaging in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2, a006213 (2012).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"21796_CR4","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1474-4422(12)70142-4","volume":"11","author":"CM Clark","year":"2012","unstructured":"Clark, C. M. et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-\u03b2 plaques: A prospective cohort study. Lancet Neurol. 11, 669\u2013678 (2012).","journal-title":"Lancet Neurol."},{"issue":"8","key":"21796_CR5","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/acn3.81","volume":"1","author":"N Mattsson","year":"2014","unstructured":"Mattsson, N. et al. Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer\u2019s disease. Ann. Clin. Transl. Neurol. 1(8), 534\u2013543 (2014).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"21796_CR6","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/S0197-4580(01)00309-8","volume":"23","author":"M Shoji","year":"2002","unstructured":"Shoji, M. et al. Cerebrospinal fluid tau in dementia disorders: a large scale multicenter study by a Japanese study group. Neurobiol. Aging 23, 363\u2013370 (2002).","journal-title":"Neurobiol. Aging"},{"key":"21796_CR7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jalz.2011.07.004","volume":"8","author":"H Vanderstichele","year":"2012","unstructured":"Vanderstichele, H. et al. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer\u2019s disease diagnosis: A consensus paper from the Alzheimer\u2019s Biomarkers Standardization Initiative. Alzheimers Dement. 8, 65\u201373 (2012).","journal-title":"Alzheimers Dement."},{"key":"21796_CR8","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1007\/s00415-013-7047-3","volume":"260","author":"L Kaerst","year":"2013","unstructured":"Kaerst, L. et al. Cerebrospinal fluid biomarkers in Alzheimer\u2019s disease, vascular dementia, and ischemic stroke patients: a critical analysis. J. Neurol. 260, 2722\u20132727 (2013).","journal-title":"J. Neurol."},{"issue":"7","key":"21796_CR9","doi-asserted-by":"publisher","first-page":"e688","DOI":"10.1212\/WNL.0000000000013211","volume":"98","author":"Y Li","year":"2022","unstructured":"Li, Y. et al. Validation of plasma amyloid-\u03b2 42\/40 for detecting alzheimer disease amyloid plaques. Neurology 98(7), e688\u2013e699. https:\/\/doi.org\/10.1212\/WNL.0000000000013211 (2022).","journal-title":"Neurology"},{"issue":"8","key":"21796_CR10","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist, S. et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 324(8), 772\u2013781. https:\/\/doi.org\/10.1001\/jama.2020.12134 (2020).","journal-title":"JAMA"},{"issue":"2","key":"21796_CR11","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1001\/jamaneurol.2020.4201","volume":"78","author":"S Janelidze","year":"2021","unstructured":"Janelidze, S. et al. Associations of plasma phospho-tau217 levels with tau positron emission tomography in early Alzheimer disease. JAMA Neurol. 78(2), 149\u2013156. https:\/\/doi.org\/10.1001\/jamaneurol.2020.4201 (2021).","journal-title":"JAMA Neurol."},{"issue":"9","key":"21796_CR12","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S1474-4422(21)00214-3","volume":"20","author":"EH Thijssen","year":"2021","unstructured":"Thijssen, E. H. et al. Advancing Research and Treatment for Frontotemporal Lobar Degeneration investigators. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer\u2019s disease and frontotemporal lobar degeneration: A retrospective diagnostic performance study. Lancet Neurol. 20(9), 739\u2013752. https:\/\/doi.org\/10.1016\/S1474-4422(21)00214-3 (2021).","journal-title":"Lancet Neurol."},{"key":"21796_CR13","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202114408","author":"A Leuzy","year":"2021","unstructured":"Leuzy, A. et al. Blood-based biomarkers for Alzheimer\u2019s disease. EMBO Mol. Med. https:\/\/doi.org\/10.15252\/emmm.202114408 (2021).","journal-title":"EMBO Mol. Med."},{"key":"21796_CR14","doi-asserted-by":"publisher","first-page":"13203","DOI":"10.1073\/pnas.0605411103","volume":"103","author":"TK Khan","year":"2006","unstructured":"Khan, T. K. & Alkon, D. L. An internally controlled peripheral biomarker for Alzheimer\u2019s disease: Erk1 and Erk2 responses to the inflammatory signal bradykinin. Proc. Natl. Acad. Sci. USA 103, 13203\u201313207 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"21796_CR15","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/00002093-200210000-00001","volume":"16","author":"WW Barker","year":"2002","unstructured":"Barker, W. W. et al. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the state of Florida Brain Bank. Alzheimer Dis. Assoc. Disord. 16(4), 203\u2013212. https:\/\/doi.org\/10.1097\/00002093-200210000-00001 (2002).","journal-title":"Alzheimer Dis. Assoc. Disord."},{"issue":"1","key":"21796_CR16","doi-asserted-by":"publisher","first-page":"e2031654","DOI":"10.1001\/jamanetworkopen.2020.31654","volume":"4","author":"N Beker","year":"2021","unstructured":"Beker, N. et al. Association of cognitive function trajectories in centenarians with postmortem neuropathology, physical health, and other risk factors for cognitive decline. JAMA Netw. Open 4(1), e2031654. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.31654 (2021).","journal-title":"JAMA Netw. Open"},{"key":"21796_CR17","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/neup.12189","volume":"35","author":"TG Beach","year":"2015","unstructured":"Beach, T. G. et al. Arizona study of aging and neurodegenerative disorders and brain and body donation program. Neuropathology 35, 354\u2013389 (2015).","journal-title":"Neuropathology"},{"issue":"1","key":"21796_CR18","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3233\/JAD-201213","volume":"79","author":"TG Beach","year":"2021","unstructured":"Beach, T. G. & Malek-Ahmadi, M. Alzheimer\u2019s disease neuropathological comorbidities are common in the younger-old. J. Alzheimer\u2019s Dis. 79(1), 389\u2013400. https:\/\/doi.org\/10.3233\/JAD-201213 (2021).","journal-title":"J. Alzheimer\u2019s Dis."},{"issue":"17","key":"21796_CR19","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1001\/jama.2012.3556","volume":"307","author":"BD James","year":"2012","unstructured":"James, B. D. et al. Dementia from Alzheimer disease and mixed pathologies in the oldest old. JAMA 307(17), 1798\u20131800 (2012).","journal-title":"JAMA"},{"issue":"6","key":"21796_CR20","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1212\/WNL.0000000000001831","volume":"85","author":"CH Kawas","year":"2015","unstructured":"Kawas, C. H. et al. Multiple pathologies are common and related to dementia in the oldest-old. Neurology 85(6), 535\u2013542. https:\/\/doi.org\/10.1212\/WNL.0000000000001831 (2015).","journal-title":"Neurology"},{"issue":"9","key":"21796_CR21","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13195-014-0082-1","volume":"6","author":"J Rahimi","year":"2014","unstructured":"Rahimi, J. & Kovacs, G. G. Prevalence of mixed pathologies in the aging brains. Alzheimers Res. Ther. 6(9), 82. https:\/\/doi.org\/10.1186\/s13195-014-0082-1 (2014).","journal-title":"Alzheimers Res. Ther."},{"issue":"2","key":"21796_CR22","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1093\/jnen\/64.2.156","volume":"64","author":"I Mikolaenko","year":"2005","unstructured":"Mikolaenko, I. et al. Alpha-synuclein lesions in normal aging, Parkinson disease, and Alzheimer disease: Evidence from the baltimore longitudinal study of aging (BLSA). J. Neuropathol. Exp. Neurol. 64(2), 156\u2013162 (2005).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"21796_CR23","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/ana.25246","volume":"84","author":"MC Power","year":"2018","unstructured":"Power, M. C. et al. (2018) Combined neuropathological pathways account for age-related risk of dementia. Ann. Neurol. 84, 10\u201322 (2018).","journal-title":"Ann. Neurol."},{"key":"21796_CR24","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1126\/science.8146663","volume":"264","author":"R Etcheberrigaray","year":"1994","unstructured":"Etcheberrigaray, R. et al. Soluble beta-amyloid induction of Alzheimer\u2019s phenotype for human fibroblast K+ channels. Science 264, 276\u2013279 (1994).","journal-title":"Science"},{"key":"21796_CR25","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3233\/JAD-141221","volume":"43","author":"TK Khan","year":"2015","unstructured":"Khan, T. K. et al. PKC\u025b deficits in Alzheimer\u2019s disease brains and skin fibroblasts. J. Alzheimer\u2019s Dis. 43, 491\u2013509 (2015).","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"21796_CR26","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1212\/WNL.43.12.2581","volume":"43","author":"S Govoni","year":"1993","unstructured":"Govoni, S. et al. Cytosol protein kinase C downregulation in fibroblasts from Alzheimer\u2019s disease patients. Neurology 43, 2581\u20132586 (1993).","journal-title":"Neurology"},{"key":"21796_CR27","doi-asserted-by":"publisher","first-page":"5562","DOI":"10.1073\/pnas.95.10.5562","volume":"95","author":"A Favit","year":"1998","unstructured":"Favit, A. et al. Alzheimer\u2019s-specific effects of soluble beta-amyloid on protein kinase C-alpha and -gamma degradation in human fibroblasts. Proc. Natl. Acad. Sci. USA 95, 5562\u20135567 (1998).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"21796_CR28","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.neulet.2008.03.046","volume":"436","author":"E Cazzaniga","year":"2008","unstructured":"Cazzaniga, E. et al. Enhanced folate binding of cultured fibroblasts from Alzheimer\u2019s disease patients. Neurosci. Lett. 436, 317\u2013320 (2008).","journal-title":"Neurosci. Lett."},{"key":"21796_CR29","doi-asserted-by":"publisher","first-page":"829","DOI":"10.3233\/JAD-2009-1193","volume":"18","author":"A Pani","year":"2009","unstructured":"Pani, A. et al. Altered cholesterol ester cycle in skin fibroblasts from patients with Alzheimer\u2019s disease. J. Alzheimers Dis. 18, 829\u2013841 (2009).","journal-title":"J. Alzheimers Dis."},{"key":"21796_CR30","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.3233\/JAD-140672","volume":"42","author":"FV Chirila","year":"2014","unstructured":"Chirila, F. V., Khan, T. K. & Alkon, D. L. Fibroblast aggregation rate converges with validated peripheral biomarkers for Alzheimer\u2019s disease. J. Alzheimer\u2019s Dis. 42, 1279\u20131294 (2014).","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"21796_CR31","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3233\/JAD-2012-120745","volume":"33","author":"FV Chirila","year":"2013","unstructured":"Chirila, F. V., Khan, T. K. & Alkon, D. L. Spatiotemporal complexity of fibroblast network screens for Alzheimer's disease. J. Alzheimer's Dis. 33, 165\u2013176 (2013).","journal-title":"J. Alzheimer's Dis."},{"key":"21796_CR32","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1002\/ana.410300410","volume":"30","author":"RD Terry","year":"1991","unstructured":"Terry, R. D. et al. (1991) Physical basis of cognitive alterations in Alzheimer\u2019s disease: Synaptic loss is the major correlate of cognitive impairment. Ann. Neurol. 30, 572\u2013580 (1991).","journal-title":"Ann. Neurol."},{"key":"21796_CR33","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S0140-6736(08)61075-2","volume":"372","author":"C Holmes","year":"2008","unstructured":"Holmes, C. et al. Long-term effects of A\u03b242 immunisation in Alzheimer\u2019s disease: Follow-up of a randomised, placebo-controlled phase I trial. Lancet 372, 216\u2013223 (2008).","journal-title":"Lancet"},{"issue":"4","key":"21796_CR34","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/ana.24125","volume":"75","author":"A Serrano-Pozo","year":"2014","unstructured":"Serrano-Pozo, A. et al. Mild to moderate Alzheimer dementia with insufficient neuropathological changes. Ann. Neurol. 75(4), 597\u2013601. https:\/\/doi.org\/10.1002\/ana.24125 (2014).","journal-title":"Ann. Neurol."},{"key":"21796_CR35","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1007\/s00109-007-0270-6","volume":"85","author":"E Zoumakis","year":"2007","unstructured":"Zoumakis, E., Kalantaridou, S. N. & Chrousos, G. P. The \u201cbrain-skin connection\u201d: Nerve growth factor-dependent pathways for stress-induced skin disorders. J. Mol. Med. 85, 1347\u20131349 (2007).","journal-title":"J. Mol. Med."},{"key":"21796_CR36","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1111\/j.1600-0625.2010.01166.x","volume":"19","author":"S Schreml","year":"2010","unstructured":"Schreml, S., Kaiser, E., Landthaler, M., Szeimies, R. M. & Babilas, P. Amyloid in skin and brain: What\u2019s the link?. Exp. Dermatol. 19, 953\u2013957 (2010).","journal-title":"Exp. Dermatol."},{"key":"21796_CR37","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/nature08797","volume":"463","author":"T Vierbuchen","year":"2010","unstructured":"Vierbuchen, T. et al. Direct conversion of fibroblasts to functional neurons by defined factors. Nature 463, 1035\u20131041 (2010).","journal-title":"Nature"},{"key":"21796_CR38","doi-asserted-by":"publisher","first-page":"3311","DOI":"10.4161\/cc.10.19.17584","volume":"10","author":"U Pfisterer","year":"2011","unstructured":"Pfisterer, U. et al. Efficient induction of functional neurons from adult human fibroblasts. Cell Cycle 10, 3311\u20133316 (2011).","journal-title":"Cell Cycle"},{"key":"21796_CR39","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/nature10323","volume":"476","author":"AS Yoo","year":"2011","unstructured":"Yoo, A. S. et al. MicroRNA-mediated conversion of human fibroblasts to neurons. Nature 476, 228\u2013231 (2011).","journal-title":"Nature"},{"issue":"9","key":"21796_CR40","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/j.stem.2021.04.004","volume":"28","author":"J Mertens","year":"2021","unstructured":"Mertens, J. et al. Age-dependent instability of mature neuronal fate in induced neurons from Alzheimer\u2019s patients. Cell Stem Cell 28(9), 1533-1548.e6 (2021).","journal-title":"Cell Stem Cell"},{"key":"21796_CR41","doi-asserted-by":"publisher","first-page":"16635","DOI":"10.1038\/s41598-021-95995-4","volume":"11","author":"G Wali","year":"2021","unstructured":"Wali, G. et al. Single cell morphology distinguishes genotype and drug effect in hereditary spastic paraplegia. Sci. Rep. 11, 16635. https:\/\/doi.org\/10.1038\/s41598-021-95995-4 (2021).","journal-title":"Sci. Rep."},{"issue":"11","key":"21796_CR42","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3389\/fnins.2017.00553.PMID:29056898;PMCID:PMC5635042","volume":"6","author":"MJ P\u00e9rez","year":"2017","unstructured":"P\u00e9rez, M. J., Ponce, D. P., Osorio-Fuentealba, C., Behrens, M. I. & Quintanilla, R. A. Mitochondrial bioenergetics is altered in fibroblasts from patients with sporadic Alzheimer\u2019s disease. Front. Neurosci. 6(11), 553. https:\/\/doi.org\/10.3389\/fnins.2017.00553.PMID:29056898;PMCID:PMC5635042 (2017).","journal-title":"Front. Neurosci."},{"issue":"16","key":"21796_CR43","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1089\/ars.2016.6802","volume":"25","author":"V Bonet-Costa","year":"2016","unstructured":"Bonet-Costa, V., Pomatto, L. C. & Davies, K. J. The proteasome and oxidative stress in Alzheimer\u2019s disease. Antioxid. Redox Signal. 25(16), 886\u2013901. https:\/\/doi.org\/10.1089\/ars.2016.6802 (2016).","journal-title":"Antioxid. Redox Signal."},{"issue":"6","key":"21796_CR44","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/nn.4017","volume":"18","author":"K Herrup","year":"2015","unstructured":"Herrup, K. The case for rejecting the amyloid cascade hypothesis. Nat. Neurosci. 18(6), 794\u2013799. https:\/\/doi.org\/10.1038\/nn.4017 (2015).","journal-title":"Nat. Neurosci."},{"issue":"4","key":"21796_CR45","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/nmeth1015.PMID:17396127;PMCID:PMC2933182","volume":"4","author":"GY Lee","year":"2007","unstructured":"Lee, G. Y., Kenny, P. A., Lee, E. H. & Bissell, M. J. Three-dimensional culture models of normal and malignant breast epithelial cells. Nat. Methods 4(4), 359\u2013365. https:\/\/doi.org\/10.1038\/nmeth1015.PMID:17396127;PMCID:PMC2933182 (2007).","journal-title":"Nat. Methods"},{"issue":"16","key":"21796_CR46","doi-asserted-by":"publisher","first-page":"4949","DOI":"10.3390\/molecules26164949","volume":"26","author":"SY Lee","year":"2021","unstructured":"Lee, S. Y. et al. Three-dimensional aggregated spheroid model of hepatocellular carcinoma using a 96-pillar\/well plate. Molecules 26(16), 4949. https:\/\/doi.org\/10.3390\/molecules26164949 (2021).","journal-title":"Molecules"},{"issue":"12","key":"21796_CR47","doi-asserted-by":"publisher","first-page":"5004","DOI":"10.1091\/mbc.e05-10-0914","volume":"17","author":"CH Eng","year":"2006","unstructured":"Eng, C. H., Huckaba, T. M. & Gundersen, G. G. The formin mDia regulates GSK3beta through novel PKCs to promote microtubule stabilization but not MTOC reorientation in migrating fibroblasts. Mol. Biol. Cell 17(12), 5004\u20131506. https:\/\/doi.org\/10.1091\/mbc.e05-10-0914 (2006).","journal-title":"Mol. Biol. Cell"},{"issue":"50","key":"21796_CR48","doi-asserted-by":"publisher","first-page":"34514","DOI":"10.1074\/jbc.M109.016683","volume":"284","author":"TJ Nelson","year":"2009","unstructured":"Nelson, T. J., Cui, C., Luo, Y. & Alkon, D. L. Reduction of beta-amyloid levels by novel protein kinase C(epsilon) activators. J. Biol. Chem. 284(50), 34514\u201334521. https:\/\/doi.org\/10.1074\/jbc.M109.016683 (2009).","journal-title":"J. Biol. Chem."},{"issue":"5","key":"21796_CR49","doi-asserted-by":"publisher","first-page":"e97756","DOI":"10.1371\/journal.pone.0097756","volume":"9","author":"CS Lim","year":"2014","unstructured":"Lim, C. S. & Alkon, D. L. PKC\u03b5 promotes HuD-mediated neprilysin mRNA stability and enhances neprilysin-induced A\u03b2 degradation in brain neurons. PLoS ONE 9(5), e97756. https:\/\/doi.org\/10.1371\/journal.pone.0097756 (2014).","journal-title":"PLoS ONE"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-21796-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-21796-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-21796-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T11:07:04Z","timestamp":1667300824000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-21796-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,1]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["21796"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-21796-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,1]]},"assertion":[{"value":"8 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The following are the authors financial disclosures: \nEmployees in the company (GX, DF, GK, TK) \nStock ownership in the company (FC, DA) \nPaid Advisors (FC, DA) \nPatents (FC, TK, DA) \nOther authors have no conflicts of interest to disclose (JB, YK, GN, CW).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17675"}}